Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.22.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2023
Jan. 31, 2022
Oct. 31, 2022
Segment Reporting Information [Line Items]      
Net Loss $ (2,354) $ (3,879)  
Total operating costs and expenses 2,556 3,880  
Less non-cash share-based compensation (1,063) (2,354)  
Operating costs and expenses excluding non-cash based compensation 1,493 1,526  
Total assets 28,306   $ 30,412
Cart Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net Loss (911) (1,611)  
Operating costs and expenses excluding non-cash based compensation 598 669  
Total assets 11,318   16,921
Cancer Vaccines [Member]      
Segment Reporting Information [Line Items]      
Net Loss (958) (1,357)  
Operating costs and expenses excluding non-cash based compensation 588 480  
Total assets 11,098   9,442
Anti Viral Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net Loss (482) (904)  
Operating costs and expenses excluding non-cash based compensation 305 372  
Total assets 5,750   3,811
Other [Member]      
Segment Reporting Information [Line Items]      
Net Loss (3) (7)  
Operating costs and expenses excluding non-cash based compensation 2 $ 5  
Total assets $ 140   $ 238